MedTrace Logo

PD-1 Monoclonal Antibody Plus Apatinib Combined With SBRT in HCC With PVTT

NCT04165174 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-11-15

No results posted yet for this study

Summary

It is a trial to assess the efficacy and safety of PD-1 monoclonal antibody plus Apatinib combined with SBRT as first-line treatment in HCC with PVTT.

Conditions

Interventions

DRUG

Terepril monoclonal antibody; Apatinib

Terepril monoclonal antibody,240mg,ivdrip,Q3W Apatinib,250mg,po,QD

RADIATION

SBRT

6-10Gy/F,5-8F

Sponsors & Collaborators

  • Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Xianglin Yuan, MD,PhD · Tongji Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-31
Primary Completion
2020-11-30
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04165174 on ClinicalTrials.gov